Resources

Barrett’s esophagus learning center

Chronic reflux in the esophagus causes changes to the molecular and cellular features of the esophagus, which often results in a condition called Barrett’s esophagus. Barrett’s is a serious complication of GERD and a known risk factor for the development of esophageal cancer. Learn more about risk factors, histology, diagnosis, treatment and cancer risk.

Learn More
Graphic of where the Esophagus connects to the stomach

Case studies

  • TissueCypher reveals a missing critical detail

    A 69-year old male patient arrived was anxious about his BE, and a TissueCypher high-risk score led to a revealing discussion. 

    View case

  • Helping an older patient be proactive in preventing EAC

    An 81-year old male patient found himself on the fence about whether to continue ongoing surveillance of his BE. 

    View case

  • Confirming low risk of progression in a young female patient

    See how Dr. Yepuri handled the case of a young female patient who received an unexpected diagnosis of Barrett’s esophagus.

    View case

  • A patient with multiple EGDs and conflicting endoscopic findings

    This case of a 75-year-old female required Dr. Yepuri to weigh multiple conflicting data points to recommend the best care for an anxious patient.

    View case

  • Downstaging a patient referral for radio-frequency ablation

    This case of a 52-year-old male gives an example of how the decision on whether or not to pursue EET is not always clear.

    View case

Scientific evidence

  • Risk-aligned management guided by the tissue systems pathology test can improve health outcomes in Barrett’s esophagus and reduce healthcare-associated costs

    01 Oct 2024

    A health economics study using a microsimulation model showed that TissueCypher-guided management is both cost-saving and helps improve patient health outcomes.

    Leggett C, et al.

    Read More

  • The tissue systems pathology test objectively risk-stratifies patients with Barrett’s esophagus results from a multicenter US clinical experience study

    01 Jul 2024

    This study highlights the clinical experience of TissueCypher testing ordered by 891 physicians in over 8,000 patients. This real-world clinical use of TissueCypher reflects the U.S. BE surveillance population with a significant proportion (93.9%) of diagnosed cases having NDBE and 94.3% of orders originating from community-based practices

    Villa N, et al.

    Read More

  • A randomized controlled study on clinical adherence to evidence-based guidelines in the management of simulated patients with Barrett’s esophagus and the clinical utility of a tissue systems pathology test: results from Q-TAB

    12 Jan 2024

    TissueCypher optimized adherence to clinical guidelines for surveillance and treatment of both BE patients at high and low risk for disease progression. Use of the test can enable physicians to make risk-aligned management decisions, leading to improved patient health outcomes.  

    Peabody J, et al.

    Read More

  • An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients with Barrett's Esophagus

    01 Nov 2023

    Management guided by the TissueCypher test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.

    Duits L, et al.

    Read More

  • A Tissue Systems Pathology Test Outperforms the Standard of Care Variables in Predicting Progression in Patients with Barrett’s Esophagus

    01 Nov 2023

    This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.

    Davison J, et al.

    Read More
View all